Anti-EGFRvIII-directed CAR-T cell therapy (Shenzhen BinDeBio)

N/A

Report date: 2024/11/22 20:00:28

Base Information

Drug NameAnti-EGFRvIII-directed CAR-T cell therapy (Shenzhen BinDeBio)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsStomach NeoplasmsEsophageal NeoplasmsCarcinoma, Hepatocellular +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaPending
Originator CompaniesDehe Biotech Co LtdShenzhen Bindebio Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesShenzhen Bindebio Ltd
Active IndicationsN/A
Inactive IndicationsStomach NeoplasmsEsophageal NeoplasmsCarcinoma, Hepatocellular +[4] 

Other Information

ATC CodeN/A
Related LinksN/A